TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36261843

Group type: EXPERIMENTAL
Intervention: HP/LGI diet
Number of subjects: 744
Study: 36261882

Group type: EXPERIMENTAL
Intervention: Chinese version of the revised Fibromyalgia Impact Questionnaire (CFIQR)
Number of subjects: 200
Study: 36262060

Group type: EXPERIMENTAL
Intervention: South Asian patients with T2D
Number of subjects: 89
Study: 36262558

Group type: EXPERIMENTAL
Intervention: Coronary microvascular dysfunction (CMD) defined as coronary flow reserve (CFR) <2.3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body composition analysis and adenosine stress echocardiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LV end-diastolic pressure assessment using coronary angiography
Number of subjects: 0
Study: 36262741

Group type: EXPERIMENTAL
Intervention: Contrast-Induced Acute Kidney Injury (CI-AKI)
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: CI-AKI
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Achieving optimum body weight before CAG
Number of subjects: 594
Study: 36262832

Group type: EXPERIMENTAL
Intervention: Dry electrode EEG for prehospital detection of LVO-a stroke
Number of subjects: 386
Study: 36262914

Group type: EXPERIMENTAL
Intervention: Auditory-motor intervention with rhythmic entrainment cues and augmented auditory feedback during nine sessions.
Number of subjects: 28
Study: 36263107

Group type: EXPERIMENTAL
Intervention: Short-term follow-up of surrogate biomarkers (plasma N-terminal pro-brain natriuretic peptide, growth differentiation factor 15, troponin-T, high-sensitivity C-reactive protein, urinary albumin/creatinine ratio) obtained within 1 month and 6 months after discharge.
Number of subjects: 0
Study: 36263287

Group type: EXPERIMENTAL
Intervention: QRS duration ≥ 150 ms
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: 130 ms ≤ QRS < 150 ms
Number of subjects: 211

Group type: COMPARATOR
Intervention: QRS duration < 130 ms
Number of subjects: 211
Study: 36263311

Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Bridge-enhanced ACL restoration (BEAR)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Surgically treated ACLs
Number of subjects: 98

Group type: COMPARATOR
Intervention: Statistical parametric mapping
Number of subjects: 98

Group type: COMPARATOR
Intervention: Correlations with body and knee size
Number of subjects: 98
Study: 36263396

Group type: EXPERIMENTAL
Intervention: HPV testing in self-collected urine samples
Number of subjects: 195
Study: 36263398

Group type: EXPERIMENTAL
Intervention: Advanced supportive care for EVD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PREDS score
Number of subjects: 0
Study: 36263685

Group type: EXPERIMENTAL
Intervention: ACS patients
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Serum cortisol1 mg DST
Number of subjects: 27
Study: 36263798

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36263839

Group type: EXPERIMENTAL
Intervention: Positron emission tomography/computed tomography (PET/CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment without PET/CT
Number of subjects: 0
Study: 36263840

Group type: EXPERIMENTAL
Intervention: KTE-X19 (2×10^6 CAR T cells/kg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: KTE-X19 (1×10^6 CAR T cells/kg in 68 mL formulation)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: KTE-X19 (1×10^6 CAR T cells/kg in 40 mL formulation)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: KTE-X19 (all treated patients)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: KTE-X19 (responders)
Number of subjects: 31
Study: 36263851

Group type: EXPERIMENTAL
Intervention: Cluster 1 (n=88) - low symptoms; Cluster 2 (n=91) - mild symptoms; Cluster 3 (n=80) - isolated aesthetic discomfort; Cluster 4 (n=42) - high pain, stiffness, and functional limitation; Cluster 5 (n=88) - high pain, stiffness, functional limitation, and high aesthetic discomfort.
Number of subjects: 389
Study: 36263879

Group type: EXPERIMENTAL
Intervention: Mid Upper Arm Circumference (MUAC)
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 1117
Study: 36263947

Group type: EXPERIMENTAL
Intervention: Turkish version of the De-Morton Mobility Index (DEMMI)
Number of subjects: 102
Study: 36264113

Group type: EXPERIMENTAL
Intervention: Teenagers with obesity
Number of subjects: 5275

Group type: EXPERIMENTAL
Intervention: Caregivers of teenagers with obesity
Number of subjects: 5275

Group type: EXPERIMENTAL
Intervention: Doctors providing medical care for teenagers with obesity
Number of subjects: 5275

Group type: EXPERIMENTAL
Intervention: Communication between teenagers, caregivers, and doctors
Number of subjects: 5275
Study: 36264123

Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg/300 mg once daily + osimertinib 80 mg once daily
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Savolitinib + osimertinib combination
Number of subjects: 180
Study: 36264125

Group type: EXPERIMENTAL
Intervention: Vonoprazan (10 mg once daily)
Number of subjects: 1268
Study: 36264281

Group type: EXPERIMENTAL
Intervention: Riboflavin deficiency (EGRac ≥1.40) in individuals with MTHFR 677TT genotype
Number of subjects: 5612

Group type: EXPERIMENTAL
Intervention: Optimal riboflavin status (EGRac ≤1.26)
Number of subjects: 5612

Group type: EXPERIMENTAL
Intervention: Suboptimal riboflavin status (EGRac: 1.27-1.39)
Number of subjects: 5612

Group type: EXPERIMENTAL
Intervention: Riboflavin status (EGRac)
Number of subjects: 5612

Group type: EXPERIMENTAL
Intervention: Vitamin B-6 intake
Number of subjects: 5612

Group type: EXPERIMENTAL
Intervention: Supplement use
Number of subjects: 5612

Group type: EXPERIMENTAL
Intervention: Fortified food
Number of subjects: 5612

Group type: EXPERIMENTAL
Intervention: EGRac
Number of subjects: 5612

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 5612

Group type: EXPERIMENTAL
Intervention: Older adults (≥65 years)
Number of subjects: 5612
Study: 36264365

Group type: EXPERIMENTAL
Intervention: High arterial oxygen levels and high oxygen supplementation
Number of subjects: 1084
Study: 36264378

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemotherapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: EXTREME
Number of subjects: 67
Study: 36264382

Group type: EXPERIMENTAL
Intervention: Sapanisertib (TAK-228) 3 mg by mouth once daily on a continuous dosing schedule in 28-day cycle
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sapanisertib (TAK-228)
Number of subjects: 13
Study: 36264409

Group type: EXPERIMENTAL
Intervention: Interspinous fusion device
Number of subjects: 0
Study: 36264536

Group type: EXPERIMENTAL
Intervention: Pexidartinib with esomeprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pexidartinib with itraconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pexidartinib with rifampin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pexidartinib with probenecid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate CYP3A4 inhibitor (fluconazole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate CYP3A inducer (efavirenz)
Number of subjects: 0
Study: 36264570

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36264626

Group type: EXPERIMENTAL
Intervention: Program of Intensive Support in Emergency Departments (POISED) intervention for 6 months of care management by registered nurses and specialty-trained paraprofessionals.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Program of Intensive Support in Emergency Departments (POISED) intervention for 6 months of care management.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Usual care as recommended at emergency department discharge.
Number of subjects: 2
Study: 36264905

Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech BNT162b2 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RT-PCR positive cases
Number of subjects: 0

Group type: COMPARATOR
Intervention: RT-PCR negative controls
Number of subjects: 0
Study: 36264995

Group type: EXPERIMENTAL
Intervention: Involvement of pharmacists in the care trajectory of older adults with MNCDs in family medicine groups (FMGs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care without pharmacist involvement in control FMGs
Number of subjects: 0
Study: 36265042

Group type: EXPERIMENTAL
Intervention: Vocal biomarker assessment using machine learning models (Android and iOS)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Participants with anosmia and ageusia
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Machine learning models for symptom monitoring
Number of subjects: 259
Study: 36265052

Group type: EXPERIMENTAL
Intervention: 0.60 g/kg alcohol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 36265076

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection 2 mg every 4 weeks
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection 2 mg every 8 weeks
Number of subjects: 255

Group type: COMPARATOR
Intervention: Laser control
Number of subjects: 255
Study: 36265087

Group type: EXPERIMENTAL
Intervention: Venetoclax 600 mg + Idasanutlin 150 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Venetoclax 600 mg + Idasanutlin 200 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Venetoclax (various doses) + Idasanutlin (days 1-5 in 28-day cycles)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Patients with IDH1/2 mutations
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Patients with RUNX1 mutations
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Patients with TP53 mutations
Number of subjects: 56
Study: 36265128

Group type: EXPERIMENTAL
Intervention: COVID-19 in CLL patients
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Age over 70 years
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Any treatment for CLL in the last 12 months
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: COVID-19 severity (severe)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: COVID-19 severity (critical)
Number of subjects: 256
Study: 36265185

Group type: EXPERIMENTAL
Intervention: 3D echocardiographic imaging and assessment of RV global area strain (AS) at baseline and 6-month follow-up.
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Change in RV global AS over 6-month follow-up.
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Combination of changes in WHO class, BNP, and RV global AS.
Number of subjects: 95
Study: 36265570

Group type: EXPERIMENTAL
Intervention: Parents of children with IEMs requiring a restricted diet
Number of subjects: 785
Study: 36265677

Group type: EXPERIMENTAL
Intervention: Postpartum cervical length measurement at 8 hours
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Postpartum cervical length measurement at 24 hours
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Postpartum cervical length measurement at 48 hours
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Postpartum cervical length measurement at 6 weeks
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Preterm birth screening based on history of short postpartum cervix
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Preterm birth screening based on history of spontaneous preterm birth
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Combined screening of history of spontaneous preterm birth and short postpartum cervix
Number of subjects: 1384
Study: 36265962

Group type: EXPERIMENTAL
Intervention: Subcutaneous Implantable Cardioverter-Defibrillator Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transvenous Implantable Cardioverter-Defibrillator Therapy
Number of subjects: 0
Study: 36266001

Group type: EXPERIMENTAL
Intervention: ICD-detected sleep apnea (measured by weekly mean RDI)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Weekly mean RDI of ≥45 episodes/h
Number of subjects: 411

Group type: COMPARATOR
Intervention: Maximum RDI value during follow-up
Number of subjects: 411
Study: 36266008

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 165
Study: 36266153

Group type: EXPERIMENTAL
Intervention: Not applicable (this is an observational study with no intervention)
Number of subjects: 1000
Study: 36266435

Group type: EXPERIMENTAL
Intervention: Cystatin C-based estimation of glomerular filtration rate (eGFR)
Number of subjects: 0
Study: 36266449

Group type: EXPERIMENTAL
Intervention: Pre-operative carbohydrate loading
Number of subjects: 49
Study: 36266642

Group type: EXPERIMENTAL
Intervention: Diffractive trifocal intraocular lens (IOL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Refractive bifocal intraocular lens (IOL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diffractive trifocal IOL
Number of subjects: 80

Group type: COMPARATOR
Intervention: Refractive bifocal IOL
Number of subjects: 80
Study: 36266939

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 15
Study: 36267207

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (4000 IU)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Aspirin and Vitamin D3
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 104
Study: 36267321

Group type: EXPERIMENTAL
Intervention: 7-week group-format self-management intervention
Number of subjects: 453

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 453
Study: 36267356

Group type: EXPERIMENTAL
Intervention: Head computed tomography (CT) for assessment of hypoxic-ischaemic encephalopathy (HIE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized protocol for evaluation of CT images
Number of subjects: 0
Study: 36267663

Group type: EXPERIMENTAL
Intervention: Ribociclib plus Letrozole
Number of subjects: 5
Study: 36267741

Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg per day
Number of subjects: 53
Study: 36268285

Group type: EXPERIMENTAL
Intervention: Breast cancer patients from Karachi
Number of subjects: 500
Study: 36268539

Group type: EXPERIMENTAL
Intervention: Left-atrial long-axis shortening (LA LAS) assessment
Number of subjects: 1235
Study: 36268648

Group type: EXPERIMENTAL
Intervention: Intrapersonal and environmental factors
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Improving recreational access and self-efficacy
Number of subjects: 241
Study: 36268822

Group type: EXPERIMENTAL
Intervention: General Antimicrobial Stewardship Program (ASP) with a bundle of 5 educational measures
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Experimental ASP with 1-to-1 educational interviews
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: General ASP
Number of subjects: 14
Study: 36268845

Group type: EXPERIMENTAL
Intervention: Multidisciplinary management of CIP
Number of subjects: 0
Study: 36268941

Group type: EXPERIMENTAL
Intervention: AdaSim plus standard of care (SOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 0
Study: 36269092

Group type: EXPERIMENTAL
Intervention: Follicular Phase Stimulation (FS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Luteal Phase Stimulation (LS)
Number of subjects: 44
Study: 36269154

Group type: EXPERIMENTAL
Intervention: Fluorine 18
Number of subjects: 0
Study: 36269382

Group type: EXPERIMENTAL
Intervention: Isoproterenol (ISO) injections
Number of subjects: 1
Study: 36269426

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) initiated within 6 hours of life
Number of subjects: 629

Group type: COMPARATOR
Intervention: Maternities with <1999 annual births
Number of subjects: 629

Group type: COMPARATOR
Intervention: Time interval >3 hours between birth and call for transfer
Number of subjects: 629

Group type: COMPARATOR
Intervention: Time interval >3 hours between call for transfer and admission
Number of subjects: 629

Group type: COMPARATOR
Intervention: Occurrence of an undesirable event during transfer
Number of subjects: 629
Study: 36269503

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 917

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 917
Study: 36269504

Group type: EXPERIMENTAL
Intervention: Worst Itch Scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient Global Impression of Disease
Number of subjects: 0
Study: 36269530

Group type: EXPERIMENTAL
Intervention: Pre-chemotherapy IL-8
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Pre-chemotherapy TNF-α
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Chemotherapy duration above 20 weeks
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Chemotherapy dose
Number of subjects: 267
Study: 36269595

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 2122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2122
Study: 36269660

Group type: EXPERIMENTAL
Intervention: Boron neutron capture therapy (BNCT) using l-boronophenylalanine-fructose (l-BPA-F)
Number of subjects: 249
Study: 36269662

Group type: EXPERIMENTAL
Intervention: MyADHD intervention
Number of subjects: 5
Study: 36269731

Group type: EXPERIMENTAL
Intervention: Analgosedation (specifically ketamine)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Cumulative doses of ketamine
Number of subjects: 134
Study: 36269797

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg/day orally; 14 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RNA-seq and proteomic studies
Number of subjects: 20
Study: 36269898

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) infusion (target dose 0.75 × 10^6 CAR+ T cells/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) infusion
Number of subjects: 48
Study: 36269899

Group type: EXPERIMENTAL
Intervention: PET-adapted therapy (doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by interim PET), followed by additional cycles based on PET results.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: PET-adapted therapy (doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by interim PET), followed by intensified treatment for PET2+ patients.
Number of subjects: 94
Study: 36270020

Group type: EXPERIMENTAL
Intervention: QIDS
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: PHQ
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CES-D
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Mood Disorder Questionnaire (MDQ)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Hypomania Checklist (HCL)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Quality of Sleep
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Temperament Traits
Number of subjects: 78
Study: 36270063

Group type: EXPERIMENTAL
Intervention: High RNT (H-RNT)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Low RNT (L-RNT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 124
Study: 36270474

Group type: EXPERIMENTAL
Intervention: Image guided intensity modulated radiotherapy (IG-IMRT)
Number of subjects: 0
Study: 36270615

Group type: EXPERIMENTAL
Intervention: Straight leg raise (SLR) maneuver during high-resolution manometry (HRM)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Increase of 11 mm Hg of peak IEP from baseline during SLR
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: SLR maneuver
Number of subjects: 295
Study: 36270733

Group type: EXPERIMENTAL
Intervention: Durvalumab (750 mg every 2 weeks)
Number of subjects: 46
Study: 36270753

Group type: EXPERIMENTAL
Intervention: Danvatirsen monotherapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Danvatirsen plus durvalumab combination therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Danvatirsen monotherapy and combination therapy
Number of subjects: 11
Study: 36270787

Group type: EXPERIMENTAL
Intervention: PIMSRA (Percutaneous IntraMyocardial Septal Radiofrequency Ablation)
Number of subjects: 82
Study: 36270802

Group type: EXPERIMENTAL
Intervention: Surgical intervention for pancreatic injury
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Presence of intra-abdominal abscess (IAA)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Presence of intestinal fistula
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Shock on admission
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Absence of abdominal suction drainage
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Postoperative hemorrhage (POH)
Number of subjects: 88
Study: 36270803

Group type: EXPERIMENTAL
Intervention: Chronic bilateral deep brain stimulation (DBS) leads in the subthalamic nucleus (STN)
Number of subjects: 3
Study: 36270895

Group type: EXPERIMENTAL
Intervention: IGIV-C (2 g/kg loading dose over 2 days, maximum 80 g/d; maintenance doses of 1 g/kg every 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36270952

Group type: EXPERIMENTAL
Intervention: CCTA reconstruction approach 0.50/5 (slice thickness 0.50 mm and highest strength 5 ADMIRE IR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: CCTA reconstruction approaches (various)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CCTA reconstruction approach 0.50/5
Number of subjects: 15
Study: 36271011

Group type: EXPERIMENTAL
Intervention: Weekly nab-paclitaxel for three cycles
Number of subjects: 40
Study: 36271062

Group type: EXPERIMENTAL
Intervention: Intraoperative near-infrared (NIR) lymphography with indocyanine green (ICG)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard D1 + LN dissection under white light
Number of subjects: 65
Study: 36271158

Group type: EXPERIMENTAL
Intervention: ZED8 (monovalent antibody labeled with zirconium-89)
Number of subjects: 0
Study: 36271384

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Higher baseline sympathetic tone (average SKNA ≥ 0.86 μV)
Number of subjects: 39
Study: 36271404

Group type: EXPERIMENTAL
Intervention: Tailored implementation approach
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standardized implementation approach
Number of subjects: 12
Study: 36271419

Group type: EXPERIMENTAL
Intervention: Dehydration assessed through estimated osmolality (eOSM = 2Na + 2 K + glucose + urea)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Dehydration during acute COVID-19 infection
Number of subjects: 165